Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?

The sudden surge in the stock price can be attributed to the positive investor mindset regarding Xoma's extensive and growing portfolio of assets, defined as the right to receive potential future payments related to the advancement of an underlying therapeutic candidate. Last month, the company received a milestone payment of $8.1 million from Viracta Therapeutics, related to Day One Biopharmaceuticals' sale of its Priority Review Voucher to an undisclosed buyer. The influx of cash has likely strengthened X ...